HighTower Advisors LLC Increases Stock Holdings in Immuneering Co. (NASDAQ:IMRX)

HighTower Advisors LLC increased its holdings in shares of Immuneering Co. (NASDAQ:IMRX) by 21.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 53,360 shares of the company’s stock after buying an additional 9,400 shares during the quarter. HighTower Advisors LLC owned about 0.18% of Immuneering worth $132,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Acadian Asset Management LLC acquired a new position in Immuneering during the second quarter worth approximately $67,000. Renaissance Technologies LLC acquired a new stake in shares of Immuneering during the 2nd quarter worth $447,000. XTX Topco Ltd raised its position in shares of Immuneering by 37.3% in the 2nd quarter. XTX Topco Ltd now owns 34,159 shares of the company’s stock worth $44,000 after buying an additional 9,274 shares during the period. Marshall Wace LLP acquired a new position in Immuneering in the second quarter valued at $492,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in Immuneering in the second quarter valued at $44,000. 67.65% of the stock is owned by institutional investors and hedge funds.

Immuneering Stock Performance

Shares of NASDAQ:IMRX opened at $2.18 on Friday. The company has a market cap of $67.69 million, a P/E ratio of -1.11 and a beta of -0.33. Immuneering Co. has a one year low of $1.00 and a one year high of $7.92. The business’s 50-day simple moving average is $2.01 and its 200 day simple moving average is $1.72.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the company. Morgan Stanley downgraded Immuneering from an “equal weight” rating to an “underweight” rating in a report on Friday, December 13th. Chardan Capital reissued a “buy” rating and set a $13.00 target price on shares of Immuneering in a research report on Wednesday, November 20th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $15.00 price target on shares of Immuneering in a research report on Thursday, November 14th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $12.80.

Immuneering Company Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.